Aptorum Group Ltd
NASDAQ:APM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
N
|
Ningbo Homelink Eco-iTech Co Ltd
SZSE:301193
|
CN |
APM's latest stock split occurred on Jan 23, 2023
The company executed a 1-for-10 stock split, meaning that for every 10 shares held, investors received 1 new share.
Before the split, APM traded at 0.56 per share. Afterward, the share price was about 5.51.
The adjusted shares began trading on Jan 23, 2023. This was the only stock split in APM's history.
Global
Stock Splits Monitor
| Date | Company | Split | Pre-Split Price | Post-Split Price | |
|---|---|---|---|---|---|
|
Apr 23, 2026
|
|
Red Sky Energy Ltd
ASX:ROG
|
5-for-4
x1.25
|
0.002 0.0016 AUD | 0.002 0.002 AUD |
|
Apr 23, 2026
|
J
|
Jiusheng Electric Co Ltd
SZSE:301082
|
1-for-1
x1
|
17.33 13.2508 CNY | 12.9 12.9 CNY |
|
Apr 23, 2026
|
S
|
Saudee Group Bhd
KLSE:SAUDEE
|
1-for-10
/10
|
0.01 0.1 MYR | 0.09 0.09 MYR |
|
Apr 23, 2026
|
|
Focus Technology Co Ltd
SZSE:002315
|
1-for-1
x1
|
44.3999 33.4538 CNY | 32 32 CNY |
|
Apr 22, 2026
|
S
|
Sharetronic Data Technology Co Ltd
SZSE:300857
|
1-for-1
x1
|
304.5701 217.2101 CNY | 260.76 260.76 CNY |
ROG
002315
Aptorum Group Ltd
Glance View
Aptorum Group Ltd. is a pharmaceutical company, which engages in the discovery, development, and commercializing of therapeutic assets to treat diseases with unmet medical needs. The company is pursuing therapeutic projects in neurology, infectious diseases, gastroenterology, oncology and other. Its projects include Smart-Act series, Acticule series, RPIDD, Nativus series and Claves series. SMART-ACT is a drug delivery platform, focused on orphan diseases. SMART-ACT pipeline includes SACT-1 and SACT-COV19. Its Acticule series includes ALS-4, ALS-1 and ALS-2/3. ALS-4 is an anti-virulent, non-bacterial drug candidate for staphylococcus aureus infections. ALS-1 is an antiviral therapeutic against Influenza A. ALS-3/3 is an anti-virulent, non-bacterial approach therapeutics targeting Gram-positive bacteria. RPIDD is therapeutic against infection disease. Nativus series includes NativusWell (NLS-2), nutraceutical supplement targeting women who are between 45 ad 65 years old and experiencing menopausal, premenopausal, postmenopausal syndrome.
